Table 2: Factors associated with response to peginterferon alfa-2b and ribavirin therapy.

SVR(Range or %)Non-SVR(Range or %) value

Total7426
Age (y.o.)57(24–72)57(31–78)NS
Sex (%)
 Male33(45)13(50)
 Female41(55)13(50)NS
BMI (kg/m2)23.1(15.4–30.9)21.0(18.4–26.0)NS
WBC (/ L)5100(2100–9730)5145(3000–8300)NS
Hemoglobin (g/dL)14.1(10–16)14.0(10–16)NS
Platelet (104/ L)21.7(6.9–26.5)11.5(7.3–21.1)NS
AST (IU/L)39(17–377)44(17–140)NS
ALT (IU/L)51(11–751)53(14–169)NS
TC (mg/dL)183(106–269)163(127–248)NS
177 mg/dL (%)31(42)19(73)
177 mg/dL (%)43(58)7(27)0.005
TG (mg/dL)98(56–262)83(74–176)NS
 <88 mg/dL (%)33(44)17(67)
88 mg/dL (%)41(56)9(33)NS
LDL-C (mg/dL)109(30–167)88(64–117)0.015
98 mg/dL (%)30(40)20(77)
98 mg/dL (%)44(60)6(23)0.020
HCV RNA (KIU/mL)1000(20–40900)1850(37–24200)NS
Distribution of stage of fibrosis (%)
 131(42)12(46)
 214(19)3(12)
 36(8)5(19)
 43(4)1(4)
 Unknown20(27)5(19)NS
Distribution of grade of inflammation (%)
 127(36)12(46)
 225(34)9(35)
 32(3)0(0)
 Unknown20(27)5(19)NS

Data are median (range) or frequency (%).